| Overview |
| bs-70069r-100ul |
| Dopamine Transporter, C-Terminus Antibody |
| WB, IHC |
| Specific for endogenous levels of the ~80 kDa DAT protein. Diffuse band may be observed between ~70-85 kDa due to variable glycosylation. |
| Human, Mouse, Rat, Non-Human Primate |
| Specifications |
| Unconjugated |
| Rabbit |
| Synthetic peptide corresponding to amino acid residues from the intracellular C-terminal region of human dopamine transporter, conjugated to keyhole limpet hemocyanin (KLH). |
| Polyclonal |
| IgG |
| Lot Dependent |
| Antigen Affinity purification from Pooled whole antiserum |
| 10 mM HEPES (pH 7.5), 150 mM NaCl, 100 µg per ml BSA and 50% glycerol. |
| Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. |
| Target |
| 6531 |
| Q01959 |
| DA transporter antibody, DAT 1 antibody, DAT antibody, DAT1 antibody, Dopamine transporter 1 antibody, Dopamine transporter antibody, PKDYS antibody, SC6A3_HUMAN antibody, SLC6A3 antibody, Sodium dependent dopamine transporter antibody, Sodium-dependent dopamine transporter antibody, Solute carrier family 6 (neurotransmitter transporter dopamine) member 3 antibody, Solute carrier family 6 (neurotransmitter transporter) member 3 antibody, Solute carrier family 6 member 3 antibody, Variable number tandem repeat (VNTR) antibody |
| The dopamine transporter (DAT) is responsible for the reaccumulation of dopamine after it has been released. DAT antibodies and antibodies for other markers of catecholamine biosynthesis are widely used as markers for dopaminergic and noradrenergic neurons in a variety of applications including depression, schizophrenia, Parkinson’s disease and drug abuse (Kish et al., 2001; Zhu et al., 2000; Zhu et al., 1999). Levels of DAT protein expression are altered by chronic drug administration (Wilson et al., 1996). |
| Application Dilution |
| WB |
1:300-5000 |
| IHC |
|
Powered by Bioz